Citation Impact
Citing Papers
Glioblastoma Cells Require Glutamate Dehydrogenase to Survive Impairments of Glucose Metabolism or Akt Signaling
2009
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
2012
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
2013
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Coevolution of Solid Stress and Interstitial Fluid Pressure in Tumors During Progression: Implications for Vascular Collapse
2013
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
2017
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
Analysis of Hypoxia-Induced Metabolic Reprogramming
2014 StandoutNobel
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
2014
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Smarter drugs emerging in pancreatic cancer therapy
2014
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
2010
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Pancreatic cancer genomics
2014
Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
2014
Breast cancer
2016 Standout
Targeting tumor associated macrophages: The new challenge for nanomedicine
2017
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Hepatocellular carcinoma
2016 Standout
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
2014
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
2016
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
2014
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
2013
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer
2013
The Molecular Signatures Database Hallmark Gene Set Collection
2015 Standout
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
2015
Pancreatic cancer
2016 Standout
Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
2017
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Cancer stem cells revisited
2017 Standout
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
2015 StandoutNobel
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
Control of Nutrient Stress-Induced Metabolic Reprogramming by PKCζ in Tumorigenesis
2013
In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus
2018 Standout
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
2015
Pancreatic Adenocarcinoma
2014 Standout
Cancer-associated cachexia
2018 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
2010
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Regulation of cancer cell metabolism
2011 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis
2018 StandoutNobel
High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
2020 Standout
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs
2013
Targeting the TGFβ signalling pathway in disease
2012
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
2013
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Exploiting the bad eating habits of Ras-driven cancers
2013
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
AKT/PKB Signaling: Navigating the Network
2017 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
2017
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx
2019 StandoutNobel
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Combining two strategies to improve perfusion and drug delivery in solid tumors
2013
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Fundamentals of cancer metabolism
2016 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
Seasonality of Respiratory Viral Infections
2020
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
2011
A Computational Model for Overcoming Drug Resistance Using Selective Dual-Inhibitors for Aurora Kinase A and Its T217D Variant
2013 StandoutNobel
Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
2013
Combination therapy in combating cancer
2017 Standout
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer
2013
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
2020
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Metabolic reprogramming and cancer progression
2020 StandoutScience
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
2013
Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
2012
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
2020
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
2014
Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective
2018
Airborne transmission of respiratory viruses
2021 StandoutScience
Works of Wen Wee being referenced
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
2012
Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation
2015
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
2013
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
2016
Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises
2016
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors
2014
Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy
2011
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.
2013
Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience.
2012
Abstract 1939: TL32711, a novel Smac mimetic, exerts significant antitumor efficacy in primary pancreatic adenocarcinoma model
2012
Abstract 1: Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumors in vitro and in vivo
2011
[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
2009
A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in patients (pts) with advanced cancers.
2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
2015
Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
2011
Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).
2013
Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.
2016
Pharmacodynamic-Guided Modified Continuous Reassessment Method–Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors
2008
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
2012